NANETS is now accepting abstract submissions for the 2021 Multidisciplinary NET Medical Symposium, from November 4-6, 2021, in Chicago, IL, US. The abstract submission portal is open through July 30, 12:00 AM PDT. Click here to see full instructions.

NANETS' Annual Multidisciplinary NET Medical Symposium represents an excellent opportunity to present research relevant to cutting edge topics in neuroendocrine tumor research. Medical researchers at institutions in North America and around the world are invited to submit.

For examples of successful abstracts, we encourage you to visit our website. Interested professionals can access the abstract submission portal here.

Wednesday, June 16, Mark Lewis, MD was a guest on This Pathological Life Podcast where he discussed MEN Syndromes and how "pancreatic cancer need not to be viewed as a death sentence." Listen now on Apple Podcasts and Spotify.  

"The recognition of hereditary NET syndromes can be a tip-of-the-iceberg phenomenon whereby identifying a genetic cause of neuroendocrine tumors can affect the lifelong management of the index patient and lead to the discovery of affected relatives, with the opportunity to provide genetic counseling and potentially intervene earlier in a disease arising from a germline mutation," shares Dr. Lewis.

 Risk of Cancer-Specific Death for Patients Diagnosed with Neuroendocrine Tumors: A Population-Based Analysis

NANETS members Julie Hallet, MD, MSC, FRCSC and Simron Singh, MD, MPH, FRCPC recently conducted a population-based study of patients with NETs to examine cancer and noncancer deaths after diagnosis.  

This study was published June 4 in the Official Journal of the National Comprehensive Cancer Network. Read the full analysis here.

In this study, Dr. Hallet et al used linked administrative health databases to describe the causes of death for 8607 patients with neuroendocrine neoplasms. They found that, generally, cancer-specific deaths were higher in NET patients, but some subgroups (e.g. those with nonmetastatic gastric, small intestine, colonic, and rectal NETs) were more likely to die of other causes than their NET.
Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms

NANETS member Amro Abdelrahman, MD conducted a population-based study to assess sex-based differences in prognosis of a contemporary cohort of gastroenteropancreatic-neuroendocrine neoplasm (GEP-NEN) patients.

This study was published May 5 in the NANETS affiliated medical journal Pancreas. View the full study here.
Upon joining, NANETS members receive free online access to Pancreas, a $1,678 annual value. Learn more about NANETS membership benefits on our website.